📗 Cite This Artifact
📖
GLP-1 and GIP Agonists for Neurodegeneration
active
wiki page
Created: 2026-04-02T07:19:01
By: crosslink-migration
Quality:
50%
✓ SciDEX
ID: wiki-therapeutics-glp1-gip-agonists-neur
📖 Wiki Page
therapeutic935 wordssynced 2026-04-02
GLP-1 and GIP Dual Agonists in Neurodegeneration
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 and GIP Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Insulin Signaling</td>
<td>Improve brain insulin sensitivity and glucose metabolism</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Reduce microglial activation and pro-inflammatory cytokines</td>
</tr>
<tr>
<td class="label">Synaptic Plasticity</td>
<td>Enhance [LTP](/mechanisms/long-term-potentiation), improve dendritic spine density</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Promote hippocampal neurogenesis in adult brain</td>
</tr>
<tr>
<td class="label">Mitochondrial Function</td>
<td>Improve mitochondrial biogenesis and reduce oxidative stress</td>
</tr>
<tr>
<td class="label">Protein Clearance</td>
<td>Enhance [autophagy](/entities/autophagy) and reduce protein aggregate accumulation</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Activate PI3K/Akt pathway to prevent neuronal death</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT04777396</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04777409</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04269642</td>
<td>Liraglutide</td>
</tr>
<tr>
<td class="label">NCT02953665</td>
<td>Exenatide</t...
GLP-1 and GIP Dual Agonists in Neurodegeneration
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 and GIP Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Insulin Signaling</td>
<td>Improve brain insulin sensitivity and glucose metabolism</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Reduce microglial activation and pro-inflammatory cytokines</td>
</tr>
<tr>
<td class="label">Synaptic Plasticity</td>
<td>Enhance [LTP](/mechanisms/long-term-potentiation), improve dendritic spine density</td>
</tr>
<tr>
<td class="label">Neurogenesis</td>
<td>Promote hippocampal neurogenesis in adult brain</td>
</tr>
<tr>
<td class="label">Mitochondrial Function</td>
<td>Improve mitochondrial biogenesis and reduce oxidative stress</td>
</tr>
<tr>
<td class="label">Protein Clearance</td>
<td>Enhance [autophagy](/entities/autophagy) and reduce protein aggregate accumulation</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Activate PI3K/Akt pathway to prevent neuronal death</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT04777396</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04777409</td>
<td>Semaglutide</td>
</tr>
<tr>
<td class="label">NCT04269642</td>
<td>Liraglutide</td>
</tr>
<tr>
<td class="label">NCT02953665</td>
<td>Exenatide</td>
</tr>
<tr>
<td class="label">NCT04236661</td>
<td>Liraglutide</td>
</tr>
<tr>
<td class="label">NCT05664581</td>
<td>Tirzpatide</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Receptor Target</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>GLP-1</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>GLP-1</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>GLP-1</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>GLP-1</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>GLP-1 + GIP</td>
</tr>
<tr>
<td class="label">Oral Semaglutide</td>
<td>GLP-1</td>
</tr>
</table>
Introduction
Glp 1 And Gip Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists represent a breakthrough therapeutic approach for neurodegenerative diseases. Originally developed for type 2 diabetes, these incretin hormones have shown remarkable neuroprotective properties in preclinical and clinical studies. Dual GLP-1/GIP agonists (tirzepatide) and triple agonists are now being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@athauda2017]
Molecular Mechanism
GLP-1 and GIP agonists work through multiple neuroprotective pathways: [@femminella2021]
Key Drug Candidates
Tirzepatide (Mounjaro)
- Mechanism: Dual GLP-1 and GIP receptor agonist
- Clinical Status: FDA-approved for type 2 diabetes; Phase II for AD/PD
- Evidence: Superior neuroprotection vs. GLP-1 alone in models
Semaglutide (Ozempic/Wegovy)
- Mechanism: Long-acting [GLP-1 receptor](/entities/glp1-receptor) agonist
- Clinical Status: FDA-approved for diabetes/weight loss; Phase III for AD (EVOKE/EVOKE+)
- Evidence: Reduces [Aβ](/proteins/amyloid-beta), improves cognition in AD models
Liraglutide (Victoza)
- Mechanism: GLP-1 receptor agonist (daily injection)
- Clinical Status: Approved for diabetes; Phase II completed for AD
- Evidence: Improved memory in MCI patients (ELAD trial)
Exenatide (Bydureon)
- Mechanism: GLP-1 receptor agonist (exendin-4 analog)
- Clinical Status: Approved for diabetes; Phase II for PD (completed)
- Evidence: Improved motor symptoms in PD patients
DA-CH5 (Dual Amylin/GLP-1 Agonist)
- Mechanism: Novel dual amylin and GLP-1 receptor agonist
- Clinical Status: Preclinical development
- Evidence: Enhanced neuroprotection vs. single agonists
Disease-Specific Applications
Alzheimer's Disease
- Improves brain insulin sensitivity (Type 3 diabetes hypothesis)
- Reduces [Aβ](/proteins/amyloid-beta) plaque formation and [tau](/proteins/tau) phosphorylation
- Enhances synaptic plasticity and memory function
- EVOKE/EVOKE+ Phase III trials ongoing with semaglutide
Parkinson's Disease
- Protects dopaminergic [neurons](/entities/neurons) from degeneration
- Improves motor function in PD patients
- Reduces neuroinflammation in substantia nigra
- Exenatide trial showed sustained motor improvement
Amyotrophic Lateral Sclerosis
- Modulates microglial activation
- Improves metabolic function in motor neurons
- Extends survival in preclinical models
- Clinical trials planned
Vascular Cognitive Impairment
- Improves cerebral blood flow
- Reduces vascular inflammation
- Enhances cognitive function
Clinical Trials
Comparison of Incretin Therapies
Research Directions
Current research focuses on:
- Brain-penetrant incretin analogs with enhanced CNS delivery
- Triple agonists (GLP-1/GIP/amylin) for enhanced neuroprotection
- Biomarkers to identify responders (brain insulin sensitivity)
- Combination with disease-modifying therapies
See Also
- [GLP-1 Receptor](/proteins/glp-1-receptor)
- [Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
- [Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
- [Insulin Signaling in Neurodegeneration](/mechanisms/insulin-signaling-pathway)
External Links
- [ClinicalTrials.gov - GLP-1 Neurodegeneration](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=GLP-1)
- [EVOKE Phase III Trial Information](https://clinicaltrials.gov/ct2/show/NCT04777396)
- [Incretin Therapy Review - Nature](https://pubmed.ncbi.nlm.nih.gov/?term=GLP-1+agonist+Alzheimer+disease)
Background
The study of Glp 1 And Gip Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
Related Entities
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-glp1-gip-agonists-neurodegeneration |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-48f8ef99f480 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-glp1-gip-agonists-neurodegeneration'} |
| _schema_version | 1 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
553
Outgoing
721
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
1 nodes, 0 edges
No provenance edges found
This artifact has no version history yet.
Linked Artifacts (952)
Reference URLs
Citation — BibTeX/artifacts/wiki-therapeutics-glp1-gip-agonists-neurodegeneration/cite?fmt=bibtexexport
Citation — CSL-JSON/artifacts/wiki-therapeutics-glp1-gip-agonists-neurodegeneration/cite?fmt=cslexport
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-glp1-gip-agonists-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[GLP-1 and GIP Agonists for Neurodegeneration](http://scidex.ai/artifact/wiki-therapeutics-glp1-gip-agonists-neurodegeneration)
Direct URL
http://scidex.ai/artifact/wiki-therapeutics-glp1-gip-agonists-neurodegeneration
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.